Document is current
Any future updates will be listed below
-
Authors
He, Yingge
Wang, Mengzhe
Gao, Changqing
Hao, Yonghui
He, Shuning
Li, Liqi
- License Information
-
More Information
Article History
Accepted: 29 December 2025
First Online: 15 January 2026
Declarations
:
: This meta-analysis can provide a strong numerical basis to prevent and treat skin toxicity during radiotherapy among rectoanal cancer patients by determining certain important modified influencing elements, including radiation technology (3D-CRT orvolumetric modulated arc therapy [VMAT]/intensity-modulated radiotherapy [IMRT]), total dose >50 Gy, and small bowel dosevolume parameter (small bowel volume that receives at least 45 Gy [SBV45Gy] >120 cc)–and showing how effective intervention with spray type skin protectant (Cavilon™),VMAT, HDR-ISBT and amifostine, the results provide risk-stratified, precision-based clinical practice. The obtained dose-response curves and the limits of toxicity (e.g., 50 Gy cumulative) offer actual reference values to optimise RT planning. Multimodality treatment strategies (e.g., VMAT + spray protectant+ amifostine (high risk patients)) may decrease the rate of grade III or higher radiodermatitis and interruption during treatment, improve quality of life, ensure completion and efficacy of radical radiotherapy to enhance overall oncologic outcome.
: The authors declare no competing interests.
